{"disease":{"id":"arteriosclerotic-vascular-disease","name":"Arteriosclerotic vascular disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"atorvastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"fluvastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"simvastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"rosuvastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"lovastatin","indication_name":"Arteriosclerotic vascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04866667","title":"Observational Study of ASCVD Risks of Type 2 Diabetes in East China","phase":"","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT05539781","title":"Change of Hemodynamics and Cerebral Functions After Carotid Artery Revascularization","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false}],"total":2},"guidelines":[{"drug_id":"rosuvastatin","guideline_body":"FDA label","recommendation":"To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"rosuvastatin","guideline_body":"FDA label","recommendation":"To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"rosuvastatin","guideline_body":"FDA label","recommendation":"To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"rosuvastatin","guideline_body":"FDA label","recommendation":"To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}